Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St Jude launches intracardiac ultrasound system

This article was originally published in Clinica

Executive Summary

St Jude Medical has launched its ViewMate Z intracardiac ultrasound system and ViewFlex Plus intracardiac echocardiography catheter worldwide. The ViewMate Z is designed for real-time image guidance and visualisation of the heart, to aid diagnosis or therapy during complex electrophysiology procedures such as cardiac ablation. The system was developed under St Jude's collaboration with Mountain View, California-based ultrasound specialist Zonare Medical Systems, formed two months ago (www.clinica.co.uk, 16 November 2010). It incorporates Zonare's Zone Sonography technology, which acquires data up to 10 times faster than conventional systems. The ViewFlex Plus catheter offers improved one-handed control, steering angles up to 120° and enhanced tip stability.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT096503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel